诊疗一体化与分子靶向内照射治疗:现状与未来方向
本文综述分子诊疗一体化在精准肿瘤学中的进展,已确立的放射性核素治疗包括肽受体放射性核素治疗(PRRT)、前列腺特异性膜抗原放射性配体治疗(PRLT)和间碘苄胍(MIBG)治疗,其适应证正在扩展;同时汇总了靶向成纤维细胞活化蛋白(FAPI)、趋化因子受体、整合素和胆囊收缩素受体的新型放射性诊疗药物及其潜在应用。
要点
- 诊疗一体化已整合于分化型甲状腺癌、神经内分泌肿瘤和转移性前列腺癌的管理。
- PRRT、PRLT和MIBG治疗的适应证正在扩展,并可能用于多种肿瘤的早期阶段。
- FAPI、趋化因子受体、整合素和胆囊收缩素受体靶向药物是新型诊疗方向。
核心结论
- 分子诊疗一体化已革新精准肿瘤学,并成为分化型甲状腺癌、神经内分泌肿瘤和转移性前列腺癌管理的组成部分。
- 诊疗一体化的潜力巨大,可能应用于多种肿瘤,包括其早期阶段。
主要发现
- 已确立的放射性核素治疗如PRRT、PRLT和MIBG治疗的适应证正在扩展。
- 新型放射性诊疗药物靶向成纤维细胞活化蛋白(FAPI)、趋化因子受体(pentixfor/pentixather)、整合素和胆囊收缩素受体,具有潜在应用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecular theranostics has revolutionized the field of personalized medicine, specifically augmenting "precision oncology" and is now integral in the management of malignancies like differentiated thyroid carcinoma, neuroendocrine tumors, and metastatic carcinoma prostate. The potential of theranostics is huge with possible applications in a variety of tumors, including at their early stages. This article will focus on the advancements in nuclear theranostics-highlighting the expanded indications of already established radionuclide therapies like peptide receptor radionuclide therapy (PRRT), prostate specific membrane antigen radioligand therapy (PRLT), and meta-iodobenzylguanidine therapy (MIBG therapy); and also on novel radiolabeled theranostic agents targeting fibroblast activated protein (FAPI-based radiopharmaceuticals), chemokine receptor targeting agents (pentixfor/pentixather), integrins, cholecystokinin receptors and their potential applications.
引用
- Nazar A, Basu S. Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions. Clin Nucl Med. 2025. PMID: 42247622. doi:10.1097/RLU.0000000000006120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。